| 5148- | GamB, | Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics |
| - | Review, | Var, | NA |
| 5149- | GamB, | Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells |
| - | in-vitro, | lymphoma, | JeKo-1 |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1966- | GamB, | Cisplatin, | Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | NCIH1299 |
| 1970- | GamB, | Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway |
| - | in-vitro, | Lung, | NCI-H441 |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
| 1964- | GamB, | Gambogic acid suppresses the pentose phosphate pathway by covalently inhibiting 6PGD protein in cancer cells |
| - | in-vitro, | Var, | NA |
| 1963- | GamB, | Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model |
| - | in-vitro, | Lung, | NA |
| 1962- | GamB, | HCQ, | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
| - | in-vitro, | PC, | NA |
| 1961- | GamB, | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1960- | GamB, | Vem, | Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1967- | GamB, | Gambogic acid induces apoptotic cell death in T98G glioma cells |
| - | in-vitro, | GBM, | T98G |
| - | in-vitro, | Lung, | A549 |
| 1969- | GamB, | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1956- | GamB, | Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis |
| - | in-vitro, | Melanoma, | A375 |
| 1971- | GamB, | Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vivo, | NA, | NA |
| 1972- | GamB, | doxoR, | Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression |
| - | in-vitro, | BC, | NA |
| 1973- | GamB, | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain |
| - | in-vitro, | Liver, | SMMC-7721 cell |
| 1955- | GamB, | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 1954- | GamB, | Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 2426- | GamB, | Anti-cancer natural products isolated from chinese medicinal herbs |
| - | Review, | Var, | NA |
| 7056- | GamB, | Gambogic acid induces cell death via covalent binding with PRDX1 to regulate ER stress and autophagy |
| - | in-vitro, | RCC, | 786-O |
| 7066- | GamB, | Unravelling the Therapeutic Potential of Gambogic Acid: Deciphering Its Molecular Mechanism of Action and Emerging Role as an Anticancer Xanthone |
| - | Review, | Var, | NA |
| 7065- | GamB, | Gambogic acid: A review of its pharmacological mechanisms against cancer |
| - | Review, | Var, | NA |
| 7064- | GamB, | Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Liver, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | Ovarian, | HO-8910 |
| 7063- | GamB, | Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells |
| - | vitro+vivo, | Lung, | H1299 |
| 7062- | GamB, | Chit, | Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery |
| - | in-vivo, | Nor, | NA |
| 7061- | GamB, | An open-labeled, randomized, multicentered, phase IIa study for advanced cancer treatment by gambogic acid injection (THS) |
| - | Trial, | Var, | NA |
| 7060- | GamB, | New targets for the antitumor activity of gambogic acid in hematologic malignancies |
| - | Review, | Melanoma, | RPMI-8226 |
| 7059- | GamB, | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT15 |
| 7058- | GamB, | docx, | Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells |
| - | in-vitro, | GC, | BGC-823 |
| 7057- | GamB, | Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system |
| - | in-vitro, | Var, | NA |
| 7055- | GamB, | Studies on the toxicity of gambogic acid in rats |
| - | in-vivo, | Nor, | NA |
| 7054- | GamB, | An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors |
| - | Trial, | Var, | NA |
| 7067- | GamB, | Gambogic Acid and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 7087- | GAR, | Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential |
| - | Review, | Var, | NA |
| 7086- | GAR, | Garcinol: An emerging epigenetic modifier with versatile anticancer properties |
| - | Review, | Var, | NA |
| 7085- | GAR, | Safety profile of 40% Garcinol from Garcinia indica in experimental rodents |
| - | in-vivo, | Nor, | NA |
| - | in-vivo, | Nor, | NA |
| 7088- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC4 |
| 7089- | GAR, | Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | PC, | NA |
| 7090- | GAR, | Garcinol |
| - | in-vitro, | Var, | NA |
| 7091- | GAR, | Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | Var, | NA |
| 7092- | GAR, | Garcinol and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 7093- | GAR, | Garcinol |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid